Provided by Tiger Trade Technology Pte. Ltd.

Krystal Biotech Inc.

326.21
-1.0900-0.33%
Volume:16.37K
Turnover:5.35M
Market Cap:9.66B
PE:40.95
High:330.66
Open:326.55
Low:325.15
Close:327.30
52wk High:382.54
52wk Low:179.19
Shares:29.60M
Float Shares:23.54M
Volume Ratio:1.83
T/O Rate:0.07%
Dividend:- -
Dividend Rate:- -
EPS(TTM):7.97
EPS(LYR):6.84
ROE:20.12%
ROA:9.37%
PB:7.10
PE(LYR):47.69

Loading ...

A Look At Krystal Biotech (KRYS) Valuation After UK Approval And Exclusivity Win For VYJUVEK

Simply Wall St.
·
May 25

Krystal Biotech (KRYS) Gets a Buy from Bank of America Securities

TIPRANKS
·
May 22

Corbus Pharma names Nishant Saxena chief business officer

Reuters
·
May 21

Corbus Pharmaceuticals Announces the Appointment of Nishant Saxena as Chief Business Officer and Schedules a Pre-2026 ASCO CRB-701 Data Conference Call

GlobeNewswire
·
May 21

Krystal Biotech shareholders elected Krishnan, Mason as Class III directors

Reuters
·
May 20

Krystal Biotech announces UK MHRA approval of Vyjuvek

TIPRANKS
·
May 18

Krystal Biotech wins UK MHRA approval for Vyjuvek in dystrophic epidermolysis bullosa

Reuters
·
May 18

Krystal Biotech Announces United Kingdom Mhra Approval of Vyjuvek® for the Treatment of Dystrophic Epidermolysis Bullosa

THOMSON REUTERS
·
May 18

Krystal Biotech Announces United Kingdom MHRA Approval of VYJUVEK® for the Treatment of Dystrophic Epidermolysis Bullosa

GlobeNewswire
·
May 18

The Bull Case For Krystal Biotech (KRYS) Could Change Following UK Vyjuvek Approval And Rising Profitability

Simply Wall St.
·
May 18

Analysts Are Bullish on Top Healthcare Stocks: Legend Biotech (LEGN), Krystal Biotech (KRYS)

TIPRANKS
·
May 18

Krystal Biotech's Medicine to Treat Wounds in Dystrophic Epidermolysis Bullosa Gets Approval in UK

MT Newswires Live
·
May 16

U.K.’s MHRA approves Krystal’s Vyjuvek for dystrophic epidermolysis bullosa

TIPRANKS
·
May 16

BRIEF-UK's MHRA Approves Beremagene Geperpavec For Treatment Of Dystrophic Epidermolysis Bullosa

Reuters
·
May 16

UK's Mhra: Mhra Approves Beremagene Geperpavec (Vyjuvek) for Treatment of Dystrophic Epidermolysis Bullosa

THOMSON REUTERS
·
May 16

Analysts Conflicted on These Healthcare Names: RxSight (RXST), Liquidia Technologies (LQDA) and Krystal Biotech (KRYS)

TIPRANKS
·
May 14

Krystal Biotech Inc : Bofa Global Research Raises Price Objective to $364 From $323

THOMSON REUTERS
·
May 14

There May Be Underlying Issues With The Quality Of Krystal Biotech's (NASDAQ:KRYS) Earnings

Simply Wall St.
·
May 14

Krystal Biotech (KRYS) Is Up 13.1% After Strong Q1 Earnings And FDA Nod For At-Home Vyjuvek Use – Has The Bull Case Changed?

Simply Wall St.
·
May 11

Krystal Biotech to present at BofA Securities Health Care Conference fireside chat

Reuters
·
May 07